Di Bonaventura Giovanni, Pompilio Arianna, Picciani Carla, Iezzi Manuela, D'Antonio Domenico, Piccolomini Raffaele
Laboratory of Clinical Microbiology, Department of Biomedical Sciences, G d'Annunzio University of Chiei-Pescara, Chieti, Italy.
Antimicrob Agents Chemother. 2006 Oct;50(10):3269-76. doi: 10.1128/AAC.00556-06.
Trichosporon asahii is the most common cause of fatal disseminated trichosporonosis, frequently associated with indwelling medical devices. Despite the use of antifungal drugs to treat trichosporonosis, infection is often persistent and is associated with high mortality. This drove our interest in evaluating the capability of T. asahii to form a biofilm on biomaterial-representative polystyrene surfaces through the development and optimization of a reproducible T. asahii-associated biofilm model. Time course analyses of viable counts and a formazan salt reduction assay, as well as microscopy studies, revealed that biofilm formation by T. asahii occurred in an organized fashion through four distinct developmental phases: initial adherence of yeast cells (0 to 2 h), germination and microcolony formation (2 to 4 h), filamentation (4 to 6 h), and proliferation and maturation (24 to 72 h). Scanning electron microscopy and confocal scanning laser microscopy revealed that mature T. asahii biofilms (72-h) displayed a complex, heterogeneous three-dimensional structure, consisting of a dense network of metabolically active yeast cells and hyphal elements completely embedded within exopolymeric material. Antifungal susceptibility testing demonstrated a remarkable rise in the MICs of sessile T. asahii cells against clinically used amphotericin B, caspofungin, voriconazole, and fluconazole compared to their planktonic counterparts. In particular, T. asahii biofilms were up to 16,000 times more resistant to voriconazole, the most active agent against planktonic cells (MIC, 0.06 microg/ml). Our results suggest that the ability of T. asahii to form a biofilm may be a major factor in determining persistence of the infection in spite of in vitro susceptibility of clinical isolates.
阿萨希毛孢子菌是致死性播散性毛孢子菌病最常见的病因,常与留置医疗设备相关。尽管使用抗真菌药物治疗毛孢子菌病,但感染往往持续存在且死亡率高。这促使我们有兴趣通过开发和优化可重复的阿萨希毛孢子菌相关生物膜模型,来评估阿萨希毛孢子菌在生物材料代表性聚苯乙烯表面形成生物膜的能力。活菌计数的时间进程分析、甲臜盐还原试验以及显微镜研究表明,阿萨希毛孢子菌的生物膜形成以有组织的方式经历四个不同的发育阶段:酵母细胞的初始黏附(0至2小时)、发芽和微菌落形成(2至4小时)、丝状化(4至6小时)以及增殖和成熟(24至72小时)。扫描电子显微镜和共聚焦扫描激光显微镜显示,成熟的阿萨希毛孢子菌生物膜(72小时)呈现出复杂、异质的三维结构,由代谢活跃的酵母细胞和菌丝成分组成的致密网络完全嵌入胞外聚合物材料中。抗真菌药敏试验表明,与浮游状态的阿萨希毛孢子菌细胞相比,固着状态的阿萨希毛孢子菌细胞对临床使用的两性霉素B、卡泊芬净、伏立康唑和氟康唑的最低抑菌浓度显著升高。特别是,阿萨希毛孢子菌生物膜对伏立康唑的耐药性比浮游细胞高16000倍,伏立康唑是对浮游细胞最有效的药物(最低抑菌浓度为0.06微克/毫升)。我们的结果表明,尽管临床分离株在体外敏感,但阿萨希毛孢子菌形成生物膜的能力可能是决定感染持续存在的主要因素。